TAS2R38 and COVID-19: Nevertheless, the major strength of this study is that this is the first time that polymorphisms of TAS2R38, in particular, haplotypes PAV/AVI and AVI/AVI, were investigated in relation to a possible greater prevalence or poorer outcome of COVID-19 in PCD patients.